21st week of 2009 patent applcation highlights part 53 |
Patent application number | Title | Published |
20090131260 | Solid Formulations Containing Polyalkoxylate, Method for their Production and use thereof - The invention relates to solid formulations comprising:
| 2009-05-21 |
20090131261 | Superconducting electrical cable - A superconducting electrical cable is specified, which is surrounded by a cryostat ( | 2009-05-21 |
20090131262 | METHOD OF FORMING A MULTIFILAMENT AC TOLERANT CONDUCTOR WITH STRIATED STABILIZER, ARTICLES RELATED TO THE SAME, AND DEVICES INCORPORATING THE SAME - A multifilament high temperature superconductor with thick, striated stabilizer is disclosed, including a substrate, a buffer layer, a multifilament superconductor layer, and at least one thick stabilizer layer. Also disclosed are components incorporating superconducting tapes and methods for manufacturing same. | 2009-05-21 |
20090131263 | Normalization methods for G-protein coupled receptor membrane array - Reference membrane components are either pre-labeled or labeled during assays for purposes of normalizing signals associated with binding or functional assays employing G-protein coupled receptor microarrays. A reference component may be included in a membrane in which the target GPCR is embedded or may be present in another membrane printed in conjunction with the target membrane on a microspot. Or, a GPCR microarray may be pre-labeled by incorporating a label on an exposed substrate in a defect in the printed microspot. | 2009-05-21 |
20090131264 | METHOD FOR SELECTING STABLE PROTEINS IN NON-STANDARD PHYSICOCHEMICAL CONDITIONS - The invention relates to a method for selecting proteins stable in non-standard physicochemical conditions (temperature, pressure, pH, osmolarity, salinity, solvent, etc.) comprising the expression, in an extremophilic microorganism, of variants of the protein of interest in the form of a fusion protein with a reporter protein which is stable in extreme conditions and acts as a selection marker. | 2009-05-21 |
20090131265 | BIOMARKERS FOR NEURODEGENERATIVE DISORDERS - The present invention provides methods for diagnosing neurodegenerative disease, such as Alzheimer's Disease, Parkinson's Disease, and dementia with Lewy body disease by detecting a pattern of gene product expression in a cerebrospinal fluid sample and comparing the pattern of gene product expression from the sample to a library of gene product expression pattern known to be indicative of the presence or absence of a neurodegenerative disease. The methods also provide for monitoring neurodegenerative disease progression and assessing the effects of therapeutic treatment. Also provided are kits, systems and devices for practicing the subject methods. | 2009-05-21 |
20090131266 | Nucleic Acid-Like Proteins - Provided are recombinant pentapeptide repeat family proteins comprising at least one mutation of an i | 2009-05-21 |
20090131267 | USE OF POLYMERS FOR INCREASING THE SIGNAL INTENSITY WHEN CARRYING OUT DETECTION REACTIONS - The present invention relates to increasing the signal intensity while simultaneously reducing unspecific background binding when carrying out detection reactions, in particular immunoassays by using polyvinyl derivatives. | 2009-05-21 |
20090131268 | Methods for Genotyping Polymorphisms - The invention provides method for genotyping specific sets of polymorphisms in a single multiplex reaction. The polymorphisms are selected to be of interest in detecting genetic variation that alters individuals' metabolism, distribution, extretion and transport of pharmacological compounds. In preferred aspects the genotyping employs a multiplex hybridization-based assay. In some aspects combinations of methods are employed to allow the combination of polymorphisms to be interrogated. The invention also provides nucleic acid standards for validating the performance of such hybridization-based assays. | 2009-05-21 |
20090131269 | Highly multiplexed particle-based assays - Methods are provided for detecting and optionally quantitating multiple analytes, including nucleic acid and/or polypeptide analytes, in particle-based assays that can be highly multiplexed. Compositions, systems, and kits related to the methods are also featured. | 2009-05-21 |
20090131270 | METHODS FOR THE DETECTION OF MOLECULAR INTERACTIONS WITHIN CELLS - The invention provides a method of detecting the effect of an agent of interest on the interaction between two or more polypeptides introduced into a cell. The invention also provides a method for quantifying the interaction between at least two molecules of interest, which are introduced into a cell. A method for quantifying the effects of an agent of interest or the interaction between two molecules of interest on cellular constituents or functions in the same cells is also provided. The above inventive methods can be automatically quantified by a device, such as a HCS device, and utilized in the construction of a database. | 2009-05-21 |
20090131271 | METHOD FOR DELIVERING NUCLEIC ACID AND DEVICE FOR DELIVERING NUCLEIC ACID - In a method for delivering a nucleic acid of the invention, a nucleic acid is introduced into a cell by pressing the nucleic acid supported on a surface of a solid substrate against the cell. According to the method, the nucleic acid can be delivered into the cell simply at a low cost without placing a heavy burden on the cell at a high nucleic acid delivery efficiency. By allowing the surface of the solid substrate to support the nucleic acid in the form of a complex with a polyamine or a cationic lipid and pressing it against the cell, the introduction efficiency into the cell can be further improved. In the invention, by using a nucleic acid useful for gene therapy as the nucleic acid, a high-efficiency device for gene therapy can be obtained. | 2009-05-21 |
20090131272 | TRANSPOSITION OF MAIZE AC/DS ELEMENTS IN VERTEBRATES - The present invention is directed to the use of the maize Ac/Ds transposable elements in vertebrates. | 2009-05-21 |
20090131273 | Correlating spectral position of chemical species on a substrate with molecular weight, structure and chemical reactivity - A system for directly printing a variety of chemicals, including very large molecules on the substrate, includes a channel of nanometric dimension movable with respect to a substrate on which printing is to occur or a substrate movable with respect to the channel. Precision contact of the end aperture, or tip, of the channel with the surface deposits the chemical on the surface. Precision contact can be made by normal force atomic force microscopy or by other techniques that allow controlled contact or near contact with the surface on which the chemical is to be written with fine precision. Multiple channels with multiple orifices may be provided. The channel is connected to a suitable separation device such as a high performance liquid chromatograph and the chemicals are delivered through a probe orifice onto a substrate. The nanometric scale of the probe allows the chemicals to be printed on the substrate at spacings of from several nanometers to hundreds of micrometers in a fashion correlated with some external signal from a device that signals the ejection of a specific chemical. | 2009-05-21 |
20090131274 | DIAGNOSTIC NANOSENSOR AND ITS USE IN MEDICINE - This invention relates generally to biosensor technology, and pertains more particularly to novel multifunctional biosensors based on ordered arrays of metallic, semiconductors and magnetic nano-islands for medical, biological, biochemical, chemical and environmental applications. | 2009-05-21 |
20090131275 | Method For Preparing Genome Library, And Genome Library Prepared By The Method - There is provided a first method of preparing a genome library in which PCR is carried out with the use of genomic DNA of target biological species per se or fragment thereof as a direct template and with the use of random primer or one type of primer of specified sequence so as to effect genome amplification, thereby obtaining a genuine library. There is further provided a second method of preparing a genome library in which genome of target biological species is pretreated and thereafter PCR is carried out with the use of one type of primer of inherent sequence so as to effect genome amplification, thereby obtaining a genome library. In both of the methods, a genome library can be prepared conveniently from a minute amount of sample. | 2009-05-21 |
20090131276 | DIAGNOSTIC KITS AND METHODS FOR SCD OR SCA THERAPY SELECTION - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”), or Sudden Cardiac Arrest (“SCA”) risk, are described. Novel diagnostic kits and methods employing these genetic markers are used in assessing the risk of SCD, or SCA. Methods of distinguishing patients having an increased susceptibility to SCD, or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of assessing the need for an Implantable Cardio Defibrillators (“ICD”) in a patient are taught. | 2009-05-21 |
20090131277 | PROSTATE CANCER DIAGNOSIS AND TREATMENT - The present invention relates to novel mimetopes of anti-PSMA antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastatis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. | 2009-05-21 |
20090131278 | NON-SPECIFIC BINDING RESISTANT PROTEIN ARRAYS AND METHODS FOR MAKING THE SAME - Arrays of protein-capture agents useful for the simultaneous detection of a plurality of proteins which are the expression products, or fragments thereof, of a cell or population of cells in an organism are provided. A variety of antibody arrays, in particular, are described. Methods of both making and using the arrays of protein-capture agents are also disclosed. The invention arrays are particularly useful for various proteomics applications including assessing patterns of protein expression and modification in cells. | 2009-05-21 |
20090131279 | NUCLEIC ACID FLUORESCENT STAINS - The present invention provides fluorescent dye compounds and methods of using the compounds for the staining of nucleic acids. In particular, the dye compounds comprise heterocyclic molecules with hydroxy alkyl and aromatic substituents, and the dye compounds form highly fluorescent complexes upon nucleic acid binding. | 2009-05-21 |
20090131280 | Swelling Inhibitors for Clays and Shales - Hydration of clays and shales may be inhibited during drilling operations by using a clay and shale inhibitor. The inhibitor may be used with a water based drilling fluid. The clay and shale inhibitor includes from 0.2 to 5 % by weight of a reaction product of an epoxy resin with at least one primary or secondary aliphatic or cycloaliphatic amine. | 2009-05-21 |
20090131281 | Drilling Fluid containing hydrophobin - The present invention relates to the use of at least one hydrophobin or at least one hydrophobin derivative in a drilling mud. | 2009-05-21 |
20090131282 | Solid Zirconium-based cross-linking agent and use in oil field applications - A solid zirconium cross-linking agent and use in a cross-linking composition in oil field applications such as hydraulic fracturing and plugging of permeable zones. The zirconium cross-linking agent is prepared by a process comprising contacting a zirconium complex with an alkanolamine and water at particular mole ratios of alkanolamine and water to zirconium. | 2009-05-21 |
20090131283 | IMIDAZOLINE-BASED HETEROCYCLIC FOAMERS FOR DOWNHOLE INJECTION - Disclosed are imidazoline-based foamers and corrosion inhibitors for treatment of oil and gas wells for enhanced production. The invention also includes methods of foaming a fluid by introducing the disclosed foamers to oil and gas wells. | 2009-05-21 |
20090131284 | Solid zirconium-based cross-linking agent and use in oil field applications - A solid zirconium cross-linking agent is prepared comprising zirconium and hydroxyalkylated ethylene diamine ligand. Use of the cross-linking agent in compositions for oil field applications such as hydraulic fracturing and plugging of permeable zones is also disclosed. | 2009-05-21 |
20090131285 | METHOD OF TREATING SUBTERRANEAN FORMATIONS BY IN-SITU HYDROLYSIS OF ORGANIC ACID ESTERS - An oil or gas well penetrating a subterranean formation, such as a carbonate formation, is treated with a well treatment fluid which contains an organic ester. The fluid may be an oil-in-water emulsion of the organic ester and an emulsifier or a homogeneous solution of organic ester and a water/mutual solvent solution. Acid is produced in-situ by hydrolysis of the organic ester. | 2009-05-21 |
20090131286 | Method and materials for hydraulic fracturing of wells - Hydraulic fracturing of wells by injecting a degradable polymer phase as a fracturing fluid is provided. Composition and degree of polymerization of the degradable polymer and the selection of additives may be varied to adjust the viscosity, degradation time and other properties of the fracturing fluid. Viscous degradable fluid or pellets of degradable polymer may be placed in a wellbore as an internal phase in a low viscosity carrier fluid. A polymer-continuous liquid phase may be formed at a selected location in the wellbore, usually near perforations, before the polymer phase is pressured into a formation to form a hydraulic fracture. | 2009-05-21 |
20090131287 | Inhibiting hydration of shale using a polyol and potassium formate - A substantially nonaqueous composition comprising a polyol and potassium formate is made by removing water from a mixture while heating. The polyol beneficially contains 3-50 hydroxyl groups and may be polyglycerin. The water removed may originate from a solution of one or more of the ingredients, from a condensation reaction of hydroxyl groups, and/or from an esterification reaction of hydroxyl groups on the polyol(s) and the formate groups. The composition is effective for treating shale formations in well drilling to reduce hydration and sloughing of the shale. If, in the course of treating shale formations, the polyol/potassium formate composition mixes with connate or other water, the water may be removed on returning the composition to the surface, and recycled. | 2009-05-21 |
20090131288 | POWER TRANSMISSION FLUIDS WITH IMPROVED FRICTION CHARACTERISTICS - Reaction products of maleic and/or succinic acids or anhydrides and primary aliphatic amines are disclosed as effective in reducing the static friction in power transmission fluids. | 2009-05-21 |
20090131289 | Preparation of stable nanotube dispersions in liquids - The introduction of nanotubes in a liquid provides a means for changing the physical and/or chemical properties of the liquid. Improvements in heat transfer, electrical properties, viscosity, and lubricity can be realized upon dispersion of nanotubes in liquids; however, nanotubes behave like hydrophobic particles and tend to clump together in liquids. Methods of preparing stable dispersions of nanotubes are described and surfactants/dispersants are identified which can disperse carbon nanotubes in aqueous and petroleum liquid medium. The appropriate dispersant is chosen for the carbon nanotube and the water or oil based medium and the dispersant is dissolved into the liquid medium to form a solution. The carbon nanotube is added to the dispersant containing the solution with agitation, ultrasonication, and/or combinations thereof. | 2009-05-21 |
20090131290 | ACRIDAN DERIVATIVES AS ANTIOXIDANTS - A compound having the formula: | 2009-05-21 |
20090131291 | LUBRICATING OIL COMPOSITION - The present invention provides a lubricating oil composition which is less in evaporation loss even having a low viscosity and excellent in lubricating properties such as low-temperature viscosity characteristics and anti-seizure properties and in oxidation stability, suitable for use in engines, automatic transmissions, manual transmissions, final reduction gear units, and continuously variable transmissions. The lubricating oil composition comprises (A) a lubricating base oil and (B) a poly(meth)acrylate additive in such an amount that the kinematic viscosity at 100° C. of the composition (Vc) is from 3 to 15 mm | 2009-05-21 |
20090131292 | Lubricating Oil Compositions - An automotive lubricating oil composition containing:
| 2009-05-21 |
20090131293 | DIAROMATIC AMINE DERIVATIVES AS ANTIOXIDANTS - A diaromatic amine compound having the general formula: | 2009-05-21 |
20090131294 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT - The present invention relates to a product of reaction between a primary and/or secondary amine and one or more active ingredients. By the present invention, there is provided a release of the active component over a longer period of time than by the use of the active itself. | 2009-05-21 |
20090131295 | Compositions for Removal of Metal Hard Mask Etching Residues from a Semiconductor Substrate - Compositions for removing and cleaning resist, etching residues, planarization residues, metal fluorides and/or metal oxides from a substrate are provided, the composition including a metal ion-free fluoride compound and water. The resist, etching residues, planarization residues, metal fluorides and/or metal oxides are generated during one or more patterning processes during which a metal hard mask is used. | 2009-05-21 |
20090131296 | Floor Stripper For Chemically-Resistant Crosslinked Floor Finishes - Floor finishes are stripped or deep scrubbed using a floor stripper/cleaner composition containing a phenyl-substituted alkyl alcohol, an oxygenated swelling solvent other than the phenyl-substituted alkyl alcohol, water, sufficient coupler so that the composition has a single phase, and sufficient saponification agent comprising the reaction product of a fatty acid or fatty ester with a stoichiometric excess of an alkali metal hydroxide or ammonium hydroxide so that the composition has an alkaline pH and has a reduced oily residue after stripping when compared to an otherwise similar composition that does not contain the saponification agent. The composition is useful for removing ultradurable (e.g., crosslinked) floor finishes, especially on flooring substrates that are susceptible to chemical attack. | 2009-05-21 |
20090131297 | Rinse aid composition for use in automatic dishwashing machines, and methods for manufacturing and using - A combination warewashing detergent rinse aid composition is provided according to the invention. The warewashing detergent composition includes an alkaline source and a water-soluble anion. The rinse aid composition comprises an acid. The alkaline source is provided in an amount effective to provide a use composition having a pH of at least about 8. The anion is present in sufficient amount to leave a residue of anions on the surface of the wares. The acid of the rinse aid has a sufficiently low pKa to react with the anions to form an insoluble oxide on the surface of the wares. The insoluble oxide reduces the surface tension of water on the surface of the wares thus reducing water spotting. Methods for using and manufacturing a combination warewashing detergent-rinse aid composition are provided. | 2009-05-21 |
20090131298 | Method for Producing Granulated Ammonium Nitriles - A method for producing granulated ammonium nitriles is claimed which consists in granulating and simultaneously drying an ammonium nitrile together with a binder and optionally a further additive in a pneumatically generated fluidized bed. | 2009-05-21 |
20090131299 | 3-Methylbenzyl-Isobutyrate - 3-Methylbenzyl isobutyrate is described, as is the use thereof as an odoriferous substance, in particular for imparting a green fruity head note to an odoriferous substance mixture. | 2009-05-21 |
20090131300 | Regiospecific Furan Compounds and Their Use in Fragrances - The present invention is directed to the diastereoisomeric mixture and the individual isomeric components of the formula: | 2009-05-21 |
20090131301 | METHYL CYCLOHEXANE CARBOXYLATES AND THEIR USE IN PERFUME COMPOSITIONS - The present invention a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of the following compound: | 2009-05-21 |
20090131302 | Transient receptor potential vanilloid 1 and uses thereof - The present invention describes methods of retarding the development of visceral and somatic hypersensitivities in an individual. Further, the present invention describes a potentially important role for the transient receptor potential vanilloid 1 (TRPV1) in initiation and maintenance of the chronic visceral hypersensitivity and its role in development of irritable bowel syndrome. | 2009-05-21 |
20090131303 | METHODS AND COMPOSITIONS FOR TREATING DRY EYE - The present invention is directed to ophthalmic compositions containing protease-inhibiting peptide substrates. In a preferred embodiment, the protease-inhibiting peptide substrate is gelatin. The compositions may also contain a galactomannan. In a particularly preferred embodiment, the compositions contain gelatin, a galactomannan and a borate salt. The present invention also describes methods of use of these compositions to inhibit protease MMP-9, and methods of topical administration of the compositions to the eye, particularly for the treatment of dry eye. | 2009-05-21 |
20090131304 | Semi-Synthetic Desmethyl-Vancomycin-Based Glycopeptides With Antibiotic Activity - Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of the desmethyl-vancomycin scaffold, in particular, acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this scaffolds to certain substituted amides. In addition, compounds of the invention include desmethyl-vancomycin scaffolds on which the acid moiety on the macrocyclic ring is converted to certain substituted amides and the amino substituent on the amino-substituted sugar moiety is alkylated with certain alkyl groups. Also provided are methods for synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections. | 2009-05-21 |
20090131305 | ALPHA-1 ANTITRYPSIN FOR TREATING EXACERBATION EPISODES OF PULMONARY DISEASES - The present invention relates to methods for the treatment of exacerbation periods of pulmonary diseases, particularly chronic obstructive pulmonary diseases, by administering alpha-1 antitrypsin (AAT) to a subject in need thereof. Particularly, the present invention discloses the efficient treatment of exacerbation periods of pulmonary diseases by administering AAT via inhalation. | 2009-05-21 |
20090131306 | CHEMICALLY MODIFIED CYCLIC PEPTIDES CONTAINING CELL ADHESION RECOGNITION (CAR) SEQUENCES AND USES THEREFOR - Chemically modified cyclic peptides comprising cell adhesion recognition (CAR) sequences are provided having improved properties, such as improved stability. Also provided are methods of making and using same. | 2009-05-21 |
20090131307 | PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLOSPORINS - A composition is described herein comprising cyclosporin A, polysorbate 80, a polyoxyethylene stearate, and an oil; wherein the composition is an emulsion which is ophthalmically acceptable. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein. | 2009-05-21 |
20090131308 | Splice Variants of ErbB Ligands, Compositions and Uses Thereof - The present invention relates to nucleic acid and amino acid sequences of previously unknown ErbB ligands that are splice variants of previously known ErbB ligands, to compositions comprising these sequences and uses thereof in the diagnosis, treatment, and prevention of diseases and disorders mediated by ErbB receptors. Specifically, the present invention relates to splice variants lacking the C-loop of an intact EGF domain. | 2009-05-21 |
20090131309 | ICA512 COUPLES INSULIN SECRETION AND GENE EXPRESSION IN BETA-CELLS - The present invention relates to a method for stimulating expression of peptide hormones in peptide-hormone secreting endocrine cells or neurons comprising the step of promoting in said cells or neurons the presence or activity (aa) of (i) ICA512; or (ii) a derivative thereof having ICA512 function; or (iii) a fragment of ICA512 that may be cleaved by μ-calpain giving rise to a C-terminal fragment of ICA512 wherein said C-terminal fragment has the capability of being targeted to the nucleus; or (iv) a derivative of said fragment of (iii) that may be cleaved by μ-calpain giving rise to a derivative of said C-terminal fragment of ICA512 wherein said derivative of said C-terminal fragment has the capability of being targeted to the nucleus; or (v) a fragment or derivative of ICA512 that may be cleaved by μ-calpain giving rise to a C-terminal fragment of ICA512 or derivative thereof wherein said C-terminal fragment or derivative thereof has the capability of interacting with a PIAS protein in said cells or neurons; or (vi) a fragment or derivative of ICA512 that may be cleaved by μ-calpain giving rise to a C-terminal fragment of ICA512 or derivative thereof wherein said C-terminal fragment or derivative thereof has the capability of enhancing the nuclear levels, or tyrosine phosphorylation, or DNA binding activity of STATs in said cells or neurons; or (vii) a pro-form of any one of (i) to (vi); and (ab) optionally of μ-calpain or a fragment or derivative thereof having μ-calpain function; or (b) of a C-terminal fragment of ICA512 or a derivative thereof which has the capability of being targeted to the nucleus or which has the capability of interacting with a PIAS protein or of enhancing the nuclear levels, or tyrosine phosphorylation, or DNA binding activity of STATs in said cells or neurons. Additionally, the present invention relates to a method of promoting cell proliferation of peptide-hormone secreting endocrine cells or neurons comprising the step of promoting in said cells or neurons the presence or activity (aa) of (i) ICA512; or (ii) a derivative thereof having ICA512 function; or (iii) a fragment of ICA512 that may be cleaved by μ-calpain giving rise to a C-terminal fragment of ICA512 wherein said C-terminal fragment has the capability of being targeted to the nucleus; or (iv) a derivative of said fragment of (iii) that may be cleaved by μ-calpain giving rise to a derivative of said C-terminal fragment of ICA512 wherein said derivative of said C-terminal fragment has the capability of being targeted to the nucleus; or (v) a fragment or derivative of ICA512 that may be cleaved by μ-calpain giving rise to a C-terminal fragment of ICA512 or derivative thereof wherein said C-terminal fragment or derivative thereof has the capability of interacting with a PIAS protein in said cells or neurons; or (vi) a fragment or derivative of ICA512 that may be cleaved by μ-calpain giving rise to a C-terminal fragment of ICA512 or derivative thereof wherein said C-terminal fragment or derivative thereof has the capability of enhancing the nuclear levels, or tyrosine phosphorylation, or DNA binding activity of STATs in said cells or neurons; or (vii) a pro-form of any one of (i) to (vi); and (ab) optionally of μ-caipain or a fragment or derivative thereof having μ-calpain function; or (b) of a C-terminal fragment of ICA512 or a derivative thereof which has the capability of being targeted to the nucleus or which has the capability of interacting with a PIAS protein or of enhancing the nuclear levels, or tyrosine phosphorylation, or DNA binding activity of STATs in said cells or neurons. It is preferred in accordance with the invention that said endocrine cells are β-cells and that said peptide hormone is insulin. | 2009-05-21 |
20090131310 | Mucin3 egf-like domains - The invention provides for a mucin3 polypeptide, a polypeptide including a mucin3 EGF-like domain, and nucleic acids encoding such polypeptides. The invention also provides for methods of treating an individual that has or is at risk of developing a disease or condition of the alimentary canal using such polypeptides or nucleic acids. | 2009-05-21 |
20090131311 | Method for Preventing Formation of Trisulfide Derivatives of Polypeptides - A method for reducing or substantially preventing formation of a trisulfide derivative of a polypeptide in a liquid medium containing the polypeptide ijn question comprises stripping the liquid medium with a gas, suitably a chemically unreactive gas such as nitrogen or argon. | 2009-05-21 |
20090131312 | Non-natural chemokine receptor ligands and methods of use thereof - The present invention provides non-natural CXCR3 ligands comprising the N-loop region of the iTAC and polynucleotide encoding such non-natural CXCR3 ligands. The invention additionally provides methods of treating fÊbrotic disorders, angiogenic disorders, and cancer. The methods generally involve administering to an individual in need thereof an effective amount of a non-natural CXCR3 ligand of the invention. | 2009-05-21 |
20090131313 | LKKTET AND/OR LKKTNT PEPTIDE COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING TISSUE DETERIORATION, INJURY OR DAMAGE - A pharmaceutical, ophthalmic or cosmetic combination or method utilizes a peptide agent include amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, and further utilizes a quaternary ammonium salt, wherein the agent and the salt can be administered to a subject separately or together. | 2009-05-21 |
20090131314 | Thrombospondin-1 Derived Peptides and Treatment Methods - Treatments employing the matricellular protein thrombospondin-1 (TSP-I) and related compositions are disclosed for stabilizing atherosclerotic plaque and decreasing occurrence of plaque rupture events leading to, for example, myocardial infarction, stroke, and acute limb ischemia. Various peptides, including certain synthetic peptides, related to TSP-I are also disclosed. Such peptides have utility in stabilizing plaque in various contexts, including the disease states mentioned above. Some of these peptides include one or more sequences related to active sites of TSP-I for regulating, e.g., TGF-ss1 and MMP-9 activity. Experimental data show that a representative peptide provides a beneficial effect with systemic injection of the peptide. | 2009-05-21 |
20090131315 | Treatment of Subarachnoid Hemorrhage With APO E Analogs - Novel ApoE peptide derivatives and ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including subarachnoid hemorrhage, intracerebral hemorrhage, and intraventricular hemorrhage and other brain disorders. The invention encompasses methods for treating cerebral vasospasm by administration of at least one ApoE or ApoE mimetic peptide. | 2009-05-21 |
20090131316 | GLUCAGON-LIKE PEPTIDE-1 SECRETAGOGUE, GLUCAGON-LIKE PEPTIDE-1 SECRETAGOGUE FOOD OR DRINK, INHIBITOR OF POSTPRANDIAL RISE IN BLOOD GLUCOSE, AND INHIBITORY FOOD OR DRINK OF POSTPRANDIAL RISE IN BLOOD GLUCOSE - The invention relates to a GLP-1 secretagogue and an inhibitor of postprandial rise in blood glucose, containing κ-casein as an active ingredient, and a food or drink for promoting GLP-1 secretion and an inhibitory food or drink of postprandial rise in blood glucose, containing a milk-derived casein protein wherein κ-casein accounts for 60% by mass or more of the milk-derived casein. | 2009-05-21 |
20090131317 | COMPOUNDS AND PEPTIDES THAT BIND THE TRAIL RECEPTOR - The present invention relates to peptides and compounds that bind to a TRAIL receptor or otherwise act as a TRAIL receptor agonist, as well as methods of treating human diseases using the same. In addition, methods of synthesizing the peptides and compounds described herein are provided by the present invention. | 2009-05-21 |
20090131318 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules - Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines. | 2009-05-21 |
20090131319 | Human Tumor Necrosis Factor Receptor-Like 2 - The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors. | 2009-05-21 |
20090131320 | PEPTIDES MODULATING THE ACTIVITY OF THE ENGRAILED TRANSCRIPTION FACTOR - The invention relates to peptides which can become fixed to the engrailed transcription factor and which can modulate the activity thereof. | 2009-05-21 |
20090131321 | Method of reducing injury to mammalian cells - A method of inhibiting the binding between N-methyl-D-aspartate receptors and neuronal proteins in a neuron the method comprising administering to the neuron an effective inhibiting amount of a peptide replacement agent for the NMDA receptor or neuronal protein interaction domain that effect said inhibition of the NMDA receptor neuronal protein. The method is of value in reducing the damaging effect of injury to mammalian cells. Postsynaptic density-95 protein (PSD-95) couples neuronal N-methyl-D-aspartate receptors (NMDARs) to pathways mediating excitotoxicity and ischemic brain damage. This coupling was disrupted by transducing neurons with peptides that bind to modular domains on either side of the PSD-95/NMDAR interaction complex. This treatment attenuated downstream NMDAR signaling without blocking NMDAR activity, protected cultured cortical neurons from excitotoxic insults and dramatically reduced cerebral infarction volume in rats subjected to transient focal cerebral ischemia. The treatment was effective when applied either before, or one hour after, the onset of excitotoxicity in vitro and cerebral ischemia in vivo. This approach prevents negative consequences associated with blocking NMDAR activity and constitutes practical therapy for stroke. | 2009-05-21 |
20090131327 | NOGO RECEPTOR FUNCTIONAL MOTIFS AND PEPTIDE MIMETICS RELATED THERETO AND METHODS OF USING THE SAME - The present invention provides novel isolated and purified polynucleotides and polypeptides related to functional motifs of the Nogo receptor 1 (NgR1) and use of peptides mimicking these functional motifs as antagonists to NgR1 ligands, e.g., myelin-associated glycoprotein, oligodendrocyte myelin glycoprotein, Nogo-A, Nogo-66, an antibody to Nogo receptor, an antibody to GT1b, an antibody to p75 neurotrophin receptor, and an antibody to Lingo-1, etc. The invention also provides antibodies to the mimetic peptide antagonists. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for treatments requiring axonal regeneration, i.e., reversal of the effects of NgR1 ligand binding to the NgR1 (i.e., producing inhibition of axonal growth). The present invention also is directed to novel methods for treating disorders arising from inhibition of axonal growth mediated by the binding of NgR1 ligands to the NgR1. | 2009-05-21 |
20090131328 | FURIN INHIBITORS - Inhibitors for the endoprotease furin are provided for the prevention, diagnosis, treatment, and study of human and animal pathologies, which involve furin activity. These pathologies include infections caused by bacteria and virus that exploit host furin activity. These pathologies also include diseases that involve the expression of host proproteins that are processed by furin as a part of growth, development, and maintenance of the host organism including certain cancers of the head and neck. | 2009-05-21 |
20090131329 | Treatment for allograft rejection - Provided are methods of treating a mammal at risk for allograft rejection. The methods comprise treating the mammal with a compound that reduces an interaction between a CXC chemokine and a CXC receptor. | 2009-05-21 |
20090131330 | PAR-2 AGONIST - Disclosed is a compound represented by the following general formula (1): Ar—CO-AA | 2009-05-21 |
20090131331 | Novel Nutraceutical Compositions - The present invention describes the use of MAP and/or ITP or a salt thereof as a nutraceutical, preferably a medicament. | 2009-05-21 |
20090131336 | Isoxazole Derivatives and Use Thereof - Disclosed herein are isoxazole derivaties and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/β-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed. | 2009-05-21 |
20090131337 | HAIR GROWTH COMPOSITION - The present invention provides a hair growth agent having novel action mechanism and a hair growth composition containing the agent. Specifically, the present invention provides a novel hair growth composition containing one or more kinds of epsilon-N-(gamma-glutamyl)lysine or a salt thereof. | 2009-05-21 |
20090131338 | ANESTHESIA AROUSAL COMPOSITION - A method for facilitating postoperative awakening of patients from anesthesia does not depend on the experience of anesthesiologists. Also provided are an anesthesia arousal composition for use in this method and a preparation containing a bicarbonate ion that facilitates awakening from anesthesia. Specifically, the anesthesia arousal composition is provided in the form of infusion fluid. The method for controlling and facilitating awakening from anesthesia involves administering the anesthesia arousal composition. The present invention preferably provides an anesthesia arousal composition or an acidosis-correcting composition containing sodium bicarbonate as a major component that serves as a source of the bicarbonate ion, along with each or a combination of another electrolyte, glucose and an amino acid. | 2009-05-21 |
20090131339 | COMPOUNDS HAVING NEUROPROTECTIVE PROPERTIES - The invention relates to the use of morin and mangiferin, the pharmaceutically acceptable salts, prodrugs and/or solvates thereof in the production of a pharmaceutical composition for the prevention and/or treatment of a neurodegenerative disease and symptoms associated with ageing, as well as to food compositions comprising said compounds. | 2009-05-21 |
20090131340 | USE OF FLAVONOIDS AS IMMUNOMODULATING OR IMMUNO-PROTECTIVE AGENTS IN COSMETIC AND DERMATOLOGICAL PREPARATIONS - A method of treating or prophylactically treating immunosuppression or allergic and inflammatory symptoms of skin caused by UVB radiation which comprises applying to the skin a cosmetic or dermatological composition which comprises one or more flavonoids. | 2009-05-21 |
20090131341 | Novel Dihydropseudoerythromycin Derivatives - A compound represented by the formula [I] wherein each symbol is as defined in the specification or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing the compound as an active ingredient. | 2009-05-21 |
20090131342 | Nitrosated and/or nitrosylated compounds, compositions and methods of use - The invention describes novel nitrosated and/or nitrosylated compounds of the invention and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, and at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The nitrosated and/or nitrosylated compounds of the invention are preferably nitrosated and/or nitrosylated antimicrobial compounds, nitrosated and/or nitrosylated adenosine antagonists, nitrosated and/or nitrosylated LTB4 antagonists, nitrosated and/or nitrosylated mucoregulators and nitrosated and/or nitrosylated purine agonists. The methods of the invention are preferably for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis. | 2009-05-21 |
20090131343 | USE OF BRIDGED MACROLIDES OR TYLOSIN DERIVATIVES IN TREATING INFLAMMATORY BOWEL DISEASES - The invention provides methods utilizing bridged macrolide or tylosin derivatives for the treatment of patients with inflammatory bowel diseases. The methods of the invention provide for the administration to a patient of a therapeutically effective amount of a bridged macrolide or a tylosin derivative, pharmaceutically acceptable derivatives thereof, and combinations thereof for a period of time sufficient to obtain a desired alleviation of one or more symptoms of the inflammatory bowel disease. | 2009-05-21 |
20090131344 | Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives - This invention is in the field of chemical restructuring of pharmaceutical agents known to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the anthracyclines, doxorubicin and daunorubicin, that are found to reduce levels of the pharmaceutical agent in noncancerous tissues. These orotate derivatives are equally efficacious in inhibiting the SCCAKI-1 kidney tumor in animals and the reduction in the heart tissue of doxorubicin compared with doxorubicin HCl suggests a reduction in toxicity induced by free radical generation by the anthracyclines. | 2009-05-21 |
20090131345 | Medicament and method for treating recurrent spontaneous abortion - The present invention discloses a pharmaceutical composition for treating a subject with immunological recurrent spontaneous abortion which comprises a therapeutically effective amount of a substance capable of lowering the in vivo level of antinuclear antibody. Particularly, the substance is chromosome No. 2 or fragment thereof containing fibronectin encoding gene derived from the spouse of said subject, or a mixture of chromosome No. 2 or fragment thereof containing fibronectin encoding gene derived from a plurality of males. The present invention also discloses a method for treating immunological recurrent spontaneous abortion. | 2009-05-21 |
20090131346 | ANTIBODY AND METHOD FOR IDENTIFICATION OF DENDRITIC CELLS - Method for identifying myeloid or plasmacytoid dendritic cells provided by a mammal, stimulated or unstimulated, comprising the steps of: a) preparing a cell sample; b) contracting the cell sample myeloid or plasmacytoid dendritic cells to form a complex; c) detecting the complex; characterized in that the phosphatase is the Receptor type Tyrosine Phosphatase Gamma Protein (PTPRG), acting as a specific marker of said dendritic cells, and in that the compound is a polypeptide capable of selectively bind to the PTPRG or to a fragment thereof or to a oligonucleotide complementary to a PTPRG mRNA logonucleotide in such a manner as to allow the selective recognizing of the dendritic cells in the cell sample. | 2009-05-21 |
20090131347 | IMMUNIZATION-FREE METHODS FOR TREATING ANTIGEN-STIMULATED INFLAMMATION IN A MAMMALIAN HOST AND SHIFTING THE HOST'S ANTIGEN IMMUNE RESPONSIVENESS TO A TH1 PHENOTYPE - The invention relates to methods for preventing or reducing antigen-stimulated, granulocytemediated inflammation in tissue of an antigen-sensitized mammal host by delivering an immunostimulatory oligonucleotide to the host. In addition, methods for using the immunostimulatory oligonucleotides to boost a mammal host's immune responsiveness to a sensitizing antigen (without immunization of the host by the antigen) and shifting the host's immune responsiveness to a Th1 phenotype to achieve various therapeutic ends are provided. Kits for practicing the methods of the invention are also provided. | 2009-05-21 |
20090131348 | MICRORNAS DIFFERENTIALLY EXPRESSED IN PANCREATIC DISEASES AND USES THEREOF - The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as pancreatic disease, and using the profile in assessing the condition of a patient. | 2009-05-21 |
20090131349 | Methods and Compositions for Modulating Body Weight and for Treating Weight Disorders and Related Diseases - Methods of modulating body weight and/or fat content of a subject, methods of treating or preventing weight disorders and methods of treating or preventing weight disorder related diseases are disclosed. The methods include modifying an activity or expression of a protein tyrosine phosphatase epsilon (PTPe) so as to modulate the body weight and/or fat content of the subject. Pharmaceutical compositions and articles of manufacture useful in practice of the methods are further disclosed. | 2009-05-21 |
20090131350 | Hybrid Hepatocyte Growth Factor Gene Having High Expression Efficiency of Two Heterotypes of Hepatocyte Growth Factor - The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases. | 2009-05-21 |
20090131351 | Methods, compositions, and kits for modulating tumor cell proliferation - The present invention relates to compositions, methods, and kits for modulating tumor proliferation using G-rich oligonucleotides and one or more chemotherapeutic agents. | 2009-05-21 |
20090131352 | Aptamers comprising arabinose modified nucleotides - Nucleic acid ligands (or aptamers) that form a G-tetrad containing at least one arabinose modified nucleotide are provided. Preferably, the arabinose modified nucleotide is 2′-deoxy-2′-fluoroarabinonucleotide (FANA) nucleotide. Methods of using aptamers the aptamers of the claimed invention are also provided. | 2009-05-21 |
20090131353 | Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) - The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided. | 2009-05-21 |
20090131354 | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION - The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-126, using miR-126 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA. | 2009-05-21 |
20090131355 | MULTICISTRONIC VECTORS AND METHODS FOR THEIR DESIGN - Embodiments of the present invention relate to multicistronic vectors and methods for their design. Methods and compositions of the invention include a vector including at least two cistrons, wherein a first cistron includes a first promoter and a first nucleic acid sequence encoding one or more therapeutic agents, and wherein a second cistron comprises a second promoter and a second nucleic acid sequence encoding one or more RNA molecules that interfere with the expression of a biological response modifier or the therapeutic agent, wherein the expression of the first sequence is under control of the first promoter and expression of the second sequence is under control of the second promoter. | 2009-05-21 |
20090131356 | miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3P REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION - The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3p, and using nucleic acid comprising all or part of the miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3p sequences to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA. | 2009-05-21 |
20090131357 | Compositions and methods for preventing and treating cancer via modulating UBE1L, ISG15 and/or UBP43 - Compositions and methods of using compositions that induce UBE1L or a ubiquitin-like protein ISG15, or inhibit a deconjugase UBP43 to degrade oncogenic proteins and enhance apoptosis of cancer (neoplastic) or pre-cancerous (pre-neoplastic) cells are provided. Methods for the prevention or treatment of cancer via administration of these compositions are also provided. | 2009-05-21 |
20090131358 | LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided. | 2009-05-21 |
20090131359 | ANTIFIBROTIC THERAPY - The present invention relates to methods of treating severe or rapidly progressing pulmonary fibrosis in a subject in need of a treatment thereof. The methods comprise increasing the activity of pulmonary and activation-regulated chemokine (CCL18) in the lungs of the subject, whereby increasing CCL18 activity modulates the activity of at least one antifibrotic factor in the lungs of the subject. The present invention also relates to methods of screening test procedures that may be capable of treating severe or rapidly progressing pulmonary fibrosis. | 2009-05-21 |
20090131360 | Tripartite RNAi constructs - The present invention provides compositions and methods for inhibiting expression of a target gene in a cell. The process comprises introduction of double-stranded tripartite RNAi constructs into the cells and reducing the expression of the corresponding messenger RNA in the cells. The constructs, which may be packaged in or delivered as sequestered RNAi constructs, differ from the canonical siRNA in that they comprise a tripartite structure which follows the general formula of having (1) an RNAi core (either native or abbreviated), (2) one or more terminal moieties attached to the RNAi core and optionally (3) a linker between the RNAi core and the terminal moiety. Once packaged into sequestration vehicles, the constructs are activated for gene regulation by the application of certain forms of energy | 2009-05-21 |
20090131361 | Novel Use of MLN51 Gene and Protein - The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis, particularly chronic synovitis. | 2009-05-21 |
20090131362 | USE OF DEFIBROTIDE FOR THE INHIBITION OF HEPARANASE - A study has been carried out to verify the effect of Defibrotide on the activity and expression of Heparanase enzyme on myeloma tumor cells (U266) and human microvascular endothelial cells (HMEC). The study has demonstrated that defibrotide can be effectively used for the manufacture of a medicament for the treatment of diseaseses which are positively affected by the inhibition of Heparanse and/or by the downregulation of Heparanse gene expression, such as diabetes. | 2009-05-21 |
20090131363 | Deuterated darunavir - This invention relates to novel compounds that are hydroxyethylamino sulfonamide derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel hydroxyethylamino sulfonamide derivatives that are derivatives of darunavir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a human immunodeficiency virus (HIV) protease inhibitor, such as darunavir. | 2009-05-21 |
20090131364 | BIOACTIVE FRACTION FROM ZINGIER OFFICINALE AND A PROCESS FOR THE PREPARATION THEREOF - Ulcer is a serious oxidative stress induced disease with complex pathologic events including upregulation of H | 2009-05-21 |
20090131365 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) - The present invention is directed to novel heterocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor. | 2009-05-21 |
20090131366 | Use of Amine-Borane Compounds as Anti-Microbial Agents - Use of amine-borane compounds such as amine cyanoboranes and amino carboxy boranes in the treatment of medical conditions associated with pathogenic microorganisms and particularly against drug-resistant microorganisms, in the treatment of fungal and protozoal infections is disclosed. Use of amine-borane compounds for reducing the load of microorganisms in various substrates and products is further disclosed. | 2009-05-21 |
20090131367 | Combinations of HDAC Inhibitors and Proteasome Inhibitors - Provided herein are pharmaceutical agents, pharmaceutical compositions, methods of treatment, treatment regimens and kits for the treatment of cancer. | 2009-05-21 |
20090131368 | MIXTURES OF AND METHODS OF USE FOR POLYUNSATURATED FATTY ACID-CONTAINING PHOSPHOLIPIDS AND ALKYL ETHER PHOSPHOLIPIDS SPECIES - A chemical composition of a molecular species mixture of phospholipids, purified to at least 85% purity through chromatography purification, the chemical composition contains enriched both sn-1-acyl fatty chains/sn-2-docosahexaenoic acid molecular species and sn-1-ether fatty chains/sn-2-docosahexaenoic acid molecular species, the phospholipids are selected from the group consisting of: phosphatidylcholine, phosphatidylserine and phosphatidylethanolamine. Methods using the above disclosed composition in mammals to treat various conditions. | 2009-05-21 |